Canadian International Pharma Corp. Comments on Market Activity
2489 Bellevue Avenue, West Vancouver, BC Canada V7V 1E1 . Tel 604.922.2030 . Fax 604.922.2037
Trading symbol: TSX-V - NEX: CIP.H
Canadian International Pharma Corp. Comments on Market Activity
West Vancouver, British Columbia, July 24, 2018 – Canadian International Pharma Corp. (the
“Company” or “CIPC”) has responded to a request from the Investment Industry Regulatory
Organization of Canada on behalf of the Canadian Securities Exchange, following the trading activity
occurring today in its common shares. While the Company continues to aggressively pursue its business
plans, the Company is not aware of any corporate developments or other reason for the recent market
activity and has no material undisclosed information.
The Company will continue to update the investment community on its corporate developments as
information is available and in accordance with applicable securities laws and regulatory policies.
For further information, contact Mr. Clive Shallow, Shareholder Communications, at 604-922-2030, or visit
the Company’s website at www.canpharmacorp.ca.
CANADIAN INTERNATIONAL PHARMA CORP.
“Douglas L. Mason”
____________________________________________
Douglas L. Mason, C.E.O.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX Venture
Exchange) accepts responsibility for the adequacy of accuracy of this release.
FORWARD-LOOKING STATEMENTS
This release includes certain statements that may be deemed “forward-looking statements” within the meaning of applicable
securities legislation . All statements, other than historical facts, are forward -looking statements and are generally, but not
always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “suspects”, “intends”, “estimates”, “projects”,
”targets”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. The
Company’s statements regarding business opportunities from the sale of pharmaceut ical and over the counter medications
and products and from its PharmaCert Program, its cross licencing business, the engagement of its business development
agents and attendances at upcoming conference and trade shows are forward-looking statements and although the Company
believes the expectations expressed in such forward -looking statements are based on reasonable assumptions, such
statements are not guarantees of future performance and actual results may differ mate rially from those expressed in, or
implied by, this forward-looking information. Factors that could cause actual results to differ materially from those in forward -
looking statements include such matters as market prices for the Company’s anticipated products, regulatory approvals
required for the Company’s business plans, continued availability of capital and financing, and general economic, market or
business conditions. Any forward -looking statements are expressly qualified in their entirety by this cautionary statement.
Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date such
statements were made. The Company expressly disclaims any intention or obligation to update or revise any forward -looking
statements whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein i n the
United States. The securities described herein have not been and will not be registered under the United States Securities Act
of 1933, as amended, and may not be offered or sold in the United States or to the account or benefit of a U.S. person absent
an exemption from the registration requirements of such Act.